Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart report, indicates investors are bullish.

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on ...

Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth by more than eight months, according to a study that may expand its use.

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Pfizer Inc. raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity startup Metsera Inc. The ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...